Transcript - Fosamax - Osteoporosis Medication Settlement
The Osteoporosis medication, Fosamax, sold by Merck, may be associated with bone deterioration and fractures. Since its introduction to the market in 1995, Fosamax has been linked to several serious medical problems such as osteonecrosis of the jaw or dead jaw syndrome and femur fractures.
Osteoporosis, a disease that causes bones to become weak and brittle, affects nearly eight-million women and two-million men and causes approximately 1.5 million fractures each year in the United States. Fosamax was hailed as the superior treatment for the some 40 million Americans who have or are at risk for Osteoporosis and Pagets Disease of Bone.
There are almost 5,000 cases pending against Merck in federal and state courts with victims alleging Fosamax is linked to femur fractures, bone-related injuries and osteonecrosis of the jaw. Merck has agreed to pay $27 million to about 1,200 of the outstanding 5,000 plaintiffs as part of a Fosamax settlement to resolve claims that the Osteoporosis drug caused bones in their jaw to deteriorate. The rights of the thousands of outstanding cases still seek resolution. Fosamax is still on the market but new warnings were added to alert consumers of the potential dangers of its use.
Our goal at Moll Law Group is to inform consumers of potentially dangerous products and provide assistance with the filing of claims. If you have a case and would like a prompt and confidential evaluation, please fill out our free consultation form. For free consumer safety information and case updates, visit us at legalnewsnetwork.com